Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. SPY
5. ANT
6. META
7. BA
8. INTC
9. JBLU
10. AAPL

Go back to Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by 2c

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

November 7, 2022 7:00 AM EST

  Received US FDA filing acceptance of B-VEC BLA with Priority Review designation for treatment of dystrophic epidermolysis bullosa; PDUFA target action date of February 17, 2023

  Notified of no Advisory Committee meeting or a need for Risk Evaluation and Mitigation Strategies following mid-cycle BLA review for the B-VEC application

  Received positive opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for treatment of dystrophic epidermolysis bullosa; on track to submit a marketing authorization application in fourth quarter of 2022

  Strong balance sheet, closing the quarter with $407.0... More